Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection or Disease or with Concurrent Organ Dysfunction: A Phase 2 Open Label Study. (PubMed, J Assoc Med Microbiol Infect Dis Can) - Jul 17, 2025 - "In this limited sample, letermovir for CMV treatment was safe and well tolerated. Further research is needed to determine if letermovir can be used for the treatment of refractory or resistant CMV infection or disease."
Clinical • Journal • P2 data • Acute Kidney Injury • Cardiovascular • Cytomegalovirus Infection • Hepatology • Infectious Disease • Nephrology • Pediatrics • Renal Disease • Solid Organ Transplantation • Transplantation
|
|
Alyssa Cho; Alyssa R Letourneau; Amy C Sherman; Elizabeth Moulton; Eric Zhou; Esther Arbonna-Haddad; Haesook T Kim; Isabel H Gonzalez-Bocco; Jerome Ritz; Kaiwen Chen; Katherine Beluch; Lindsey R Baden; Matthew P Cheng; Michaël Desjardins; Muneerah Aleissa; Nicolas C Issa; Robert Soiffer; Sandra Burchett; Sarah P Hammond; Sophia Koo
|